244 related articles for article (PubMed ID: 19384296)
21. [Polymorphism of methylenetetrahydrofolate reductase and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy].
Gao CM; Lu JW; Toshiro T; Wu JZ; Cao HX; Chen HQ; Feng JF; Kazuo T
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Dec; 25(12):1054-8. PubMed ID: 15769364
[TBL] [Abstract][Full Text] [Related]
22. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
Marcuello E; Altés A; Menoyo A; Rio ED; Baiget M
Cancer Chemother Pharmacol; 2006 Jun; 57(6):835-40. PubMed ID: 16187112
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM
Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
[TBL] [Abstract][Full Text] [Related]
25. Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.
Etienne-Grimaldi MC; Bennouna J; Formento JL; Douillard JY; Francoual M; Hennebelle I; Chatelut E; Francois E; Faroux R; El Hannani C; Jacob JH; Milano G
Br J Clin Pharmacol; 2012 May; 73(5):776-85. PubMed ID: 22486600
[TBL] [Abstract][Full Text] [Related]
26. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
27. Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer.
Fernández-Contreras ME; Sánchez-Hernández JJ; Guijarro M; Gisbert JP; Rivas N; García de Paredes ML; Hinojar-Gutiérrez A; Gamallo C
Oncol Rep; 2010 May; 23(5):1393-400. PubMed ID: 20372856
[TBL] [Abstract][Full Text] [Related]
28. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
[TBL] [Abstract][Full Text] [Related]
29. Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
Sulzyc-Bielicka V; Bielicki D; Binczak-Kuleta A; Kaczmarczyk M; Pioch W; Machoy-Mokrzynska A; Ciechanowicz A; Gołębiewska M; Drozdzik M
Genet Test Mol Biomarkers; 2013 Nov; 17(11):799-806. PubMed ID: 23968134
[TBL] [Abstract][Full Text] [Related]
30. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer.
Etienne-Grimaldi MC; Francoual M; Formento JL; Milano G
Pharmacogenomics; 2007 Nov; 8(11):1561-6. PubMed ID: 18034621
[TBL] [Abstract][Full Text] [Related]
31. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.
Afzal S; Jensen SA; Vainer B; Vogel U; Matsen JP; Sørensen JB; Andersen PK; Poulsen HE
Ann Oncol; 2009 Oct; 20(10):1660-6. PubMed ID: 19465420
[TBL] [Abstract][Full Text] [Related]
32. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
33. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate.
Sohn KJ; Croxford R; Yates Z; Lucock M; Kim YI
J Natl Cancer Inst; 2004 Jan; 96(2):134-44. PubMed ID: 14734703
[TBL] [Abstract][Full Text] [Related]
34. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
35. Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy.
Zawiah M; Yousef AM; Kadi T; Yousef M; Majdalawi K; Al-Yacoub S; Al-Hiary R; Tantawi D; Mukred R; Ajaj AR
Drug Metab Pers Ther; 2018 Dec; 33(4):201-205. PubMed ID: 30207288
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms of folate metabolism-related genes and survival of patients with colorectal cancer in the Korean population.
Jang MJ; Kim JW; Jeon YJ; Chong SY; Hong SP; Hwang SG; Oh D; Cho YK; Ji YG; Kim NK
Gene; 2014 Jan; 533(2):558-64. PubMed ID: 24100087
[TBL] [Abstract][Full Text] [Related]
37. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
38. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
Marcuello E; Altés A; del Rio E; César A; Menoyo A; Baiget M
Int J Cancer; 2004 Dec; 112(5):733-7. PubMed ID: 15386371
[TBL] [Abstract][Full Text] [Related]
39. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
[TBL] [Abstract][Full Text] [Related]
40. Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy.
Henríquez-Hernández LA; Murias-Rosales A; González-Hernández A; de León AC; Díaz-Chico N; Fernández-Pérez L
Cancer Epidemiol; 2010 Oct; 34(5):634-8. PubMed ID: 20638924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]